Search results for "network meta-analysi"

showing 10 items of 12 documents

Untargeted Antifungal Treatment in Nonneutropenic Critically Ill Patients: Should Further Studies Be Performed Based on Trial Sequential Analysis Res…

2018

0301 basic medicineAntifungalmedicine.medical_specialtyAntifungal Agentsempirical treatmentmedicine.drug_classCritical Illness030106 microbiologyNetwork Meta-AnalysisAntifungal drug03 medical and health sciencesMedicineHumansPharmacology (medical)untargeted treatmentEconomics PharmaceuticalIntensive care medicineLetter to the EditorCandida spp.Pharmacologyantifungal drugCritically illbusiness.industryprophylaxiEmpirical treatmentInfectious DiseasesMycosesCandida sppbusiness
researchProduct

Long-Term Efficacy of Maintenance Therapy for Multiple Myeloma: A Quantitative Synthesis of 22 Randomized Controlled Trials

2018

We aimed to quantitatively synthesize data from randomized controlled trials (RCTs) concerning maintenance for multiple myeloma (MM). We searched electronic literature databases and conference proceedings to identify relevant RCTs. We selected eligible RCTs using predefined selection criteria. We conducted meta-analysis comparing maintenance containing new agents and conventional maintenance, and subgroup analysis by transplantation status and mainstay agent as well. We performed trial sequential analysis (TSA) to determine adequacy of sample size for overall and subgroup meta-analyses. We performed network meta-analysis (NMA) to compare and rank included regimens. A total of 22 RCTs involv…

Oncologymedicine.medical_specialtySubgroup analysismaintenancelaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialMaintenance therapylawInternal medicinemedicinePharmacology (medical)030212 general & internal medicinenetwork meta-analysisOriginal ResearchLenalidomidePharmacologybusiness.industrylcsh:RM1-950Hazard ratioConfidence intervalmultiple myelomameta-analysisTransplantationtrial-sequential analysislcsh:Therapeutics. Pharmacology030220 oncology & carcinogenesisMeta-analysisbusinessmedicine.drugFrontiers in Pharmacology
researchProduct

Efficacy and acceptability of pharmacological and non-pharmacological interventions for non-specific chronic low back pain: a protocol for a systemat…

2020

Abstract Background Despite the enormous financial and humanistic burden of chronic low back pain (CLBP), there is little consensus on what constitutes the best treatment options from a multitude of competing interventions. The objective of this network meta-analysis (NMA) is to determine the relative efficacy and acceptability of primary care treatments for non-specific CLBP, with the overarching aim of providing a comprehensive evidence base for informing treatment decisions. Methods We will perform a systematic search to identify randomised controlled trials of interventions endorsed in primary care guidelines for the treatment of non-specific CLBP in adults. Information sources searched…

Adultmedicine.medical_specialtyPsychological interventionMEDLINEMedicine (miscellaneous)lcsh:Medicinenot knownlaw.inventionRS03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Randomized controlled trialMeta-Analysis as TopiclawmedicineProtocolHumansLow back pain030212 general & internal medicineFunctional abilityNetwork meta-analysisExercisebusiness.industrylcsh:RBayes TheoremLow back painClinical trialRandomized controlled trialMeta-analysisPhysical therapySystematic reviewQuality of Lifemedicine.symptombusiness030217 neurology & neurosurgerySystematic Reviews as TopicSystematic Reviews
researchProduct

Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients.

2017

Despite major therapeutic advancements, multiple myeloma (MM) is still incurable and relapsed/refractory multiple myeloma (RRMM) remains a challenge; the rational choice of the most appropriate regimen in this setting is currently undefined. We performed a systematic review and 2 standard pairwise meta-analyses to evaluate the efficacy of regimens that have been directly compared with bortezomib or immunomodulatory imide drugs (IMiDs) in head-to-head clinical trials and a network meta-analysis (NMA) to determine the relevance of each regimen on the basis of all the available direct and indirect evidence. Sixteen trials were included in the pairwise meta-analyses, and 18 trials were included…

Oncologymedicine.medical_specialtylenalidomidePharmacologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineMultiple myelomaLenalidomideLymphoid Neoplasiabusiness.industryBortezomibDaratumumabHematologymedicine.diseaseClinical trialmultiple myelomaRegimennetwork meta-analysiTolerability030220 oncology & carcinogenesisbusinessdaratumumab bortezomib030215 immunologymedicine.drugBlood advances
researchProduct

What grafting materials produce greater alveolar ridge preservation after tooth extraction? A systematic review and network meta-analysis

2021

Abstract A systematic review and network meta-analysis was conducted to compare different bone-substitute materials used for alveolar ridge preservation after tooth extraction. The electronic search was carried out on Embase, PubMed, Cochrane Library, Web of Science, Scopus, LILACS, and grey literature up to March 22, 2020 (registration number INPLASY202030005). Only randomized controlled trials were included to answer the following PICOS question: ‘What grafting materials produce greater alveolar ridge preservation after tooth extraction?’ The primary outcomes were the alveolar width resorption 1 mm below the alveolar crest and buccal height resorption in millimeters. Of the 4379 studies i…

Grafting (decision trees)Network Meta-AnalysisAlveolar Bone LossDentistryCochrane LibraryAlveolar crest03 medical and health sciences0302 clinical medicineAlveolar ProcessAlveolar ridgeHumansMedicineTooth SocketBone TransplantationBone allograftbusiness.industrySignificant differenceAlveolar Ridge Augmentation030206 dentistryResorptionOtorhinolaryngology030220 oncology & carcinogenesisMeta-analysisTooth ExtractionSurgeryOral SurgerybusinessJournal of Cranio-Maxillofacial Surgery
researchProduct

Intravitreal anti-vascular endothelial growth factors, panretinal photocoagulation and combined treatment for proliferative diabetic retinopathy: a s…

2020

Purpose: to conduct a systematic review with network meta‐analysis (NMA) of randomized clinical trials (RCTs) comparing panretinal photocoagulation (PRP) versus anti‐vascular endothelial growth factor (VEGF) treatment alone or in combination with PRP, for proliferative diabetic retinopathy (PDR).Methods: PubMed, Medline and Embase databases were searched for RCTs comparing PRP versus intravitreal anti‐VEGF therapy and/or combined PRP and intravitreal anti‐VEGF for PDR. The primary outcome measures were the mean best corrected visual acuity (BCVA) change and the regression of neovascularization. Mean change of central macular thickness (CMT), the subgroup analyses of patients without diabeti…

medicine.medical_specialtyBevacizumabgenetic structurespegaptanibmedicine.medical_treatmentPegaptanibNetwork Meta-AnalysisVisual AcuityVitrectomyAngiogenesis Inhibitorsbevacizumablaw.inventionNeovascularization03 medical and health sciences0302 clinical medicineRandomized controlled trialaflibercept; bevacizumab; intravitreal anti-VEGF; panretinal photocoagulation; pegaptanib; proliferative diabetic retinopathy; ranibizumabintravitreal anti-VEGFlawOphthalmologyVitrectomymedicineHumansranibizumabAfliberceptDiabetic RetinopathyLaser Coagulationbusiness.industryafliberceptGeneral MedicineDiabetic retinopathymedicine.diseasepanretinal photocoagulationeye diseasesOphthalmologyIntravitreal Injections030221 ophthalmology & optometrysense organsRanibizumabmedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugproliferative diabetic retinopathy
researchProduct

Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis

2021

Background & Aims A number of double, triple, and quadruple therapies have been proposed as first-line empiric treatments for Helicobacter pylori infection. However, knowledge of their worldwide and regional comparative efficacy is lacking. We examined the comparative effectiveness of all empirically used first-line regimens tested against standard triple treatment using a network meta-analysis of published randomized controlled trials. Methods Data extracted from eligible randomized controlled trials were entered into a Bayesian network meta-analysis to investigate the comparative efficacy of H pylori infection empiric first-line regimens and to explore their effectiveness rank order. The …

0301 basic medicinemedicine.medical_specialtyComparative Effectiveness ResearchTime FactorsEfficacyVonoprazanSettore MED/12 - GASTROENTEROLOGIANetwork Meta-Analysislaw.inventionHelicobacter Infections03 medical and health sciences0302 clinical medicineRandomized controlled trialDrug TherapyLevofloxacinlawInternal medicinemedicineHumansFirst-Line RegimensRandomized Controlled Trials as TopicHepatologybiologyHelicobacter pyloribusiness.industryRemission InductionSettore MED/09 - MEDICINA INTERNAGastroenterologyBayes TheoremProton Pump InhibitorsOdds ratioHelicobacter pyloribiology.organism_classificationConfidence intervalAnti-Bacterial AgentsTreatmentRegimen030104 developmental biologyTreatment OutcomeMeta-analysisCombination030211 gastroenterology & hepatologyDrug Therapy Combinationbusinessmedicine.drug
researchProduct

Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant

2022

The treatment scenario for newly-diagnosed transplant-ineligible multiple myeloma patients (NEMM) is quickly evolving. Currently, combinations of proteasome inhibitors (PI) and/or immunomodulatory drugs (IMiD) +/- the monoclonal antibody Daratumumab are used for first-line treatment, even if head-to-head comparisons are lacking. To compare efficacy and safety of these regimens, we performed a network meta-analysis (NMA) of 27 phase 2/3 randomized trials including a total of 12935 patients and 23 different schedules. Four efficacy/outcome and one safety indicators were extracted and integrated to obtain (for each treatment) the surface under the cumulative ranking-curve (SUCRA), a metric use…

multiple myelomaCancer ResearchOncologyprincipal component analysisnon-transplant eligibleI line treatment multiple myeloma network meta-analysis non-transplant eligible principal component analysisHematologyGeneral MedicineSettore MED/15 - Malattie del SangueI line treatmentnetwork meta-analysisI line treatment; multiple myeloma; network meta-analysis; non-transplant eligible; principal component analysis;
researchProduct

Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis

2022

Background: The aims of this study were to quantify the histological improvement and its risk factors in patients with NASH enrolled in the placebo arms of randomized controlled trials (RCTs), and to indirectly compare the effect of several investigational drugs for NASH on validated histological outcomes.Data synthesis: A comprehensive search was conducted to detect phase 2 and 3 RCTs comparing pharmacological interventions in patients with NASH. According to Food and Drug Administra-tion (FDA) recommendations, primary outcomes included: 1) NASH resolution without wors-ening of fibrosis; 2) At least 1-point reduction in fibrosis without worsening of NASH. Meta -analysis and meta-regression…

Liver CirrhosisNutrition and DieteticsLiverNon-alcoholic Fatty Liver DiseaseEndocrinology Diabetes and MetabolismNetwork Meta-AnalysisMeta-analysis NASH Network meta-analysisMedicine (miscellaneous)HumansVitamin EDrugs InvestigationalCardiology and Cardiovascular MedicineRandomized Controlled Trials as Topic
researchProduct

Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resi…

2020

Ceftazidime-avibactam (CZA) is a novel beta-lactam beta-lactamase inhibitor combination approved for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and for hospital-acquired/ventilator-associated pneumonia. The aim of this systematic review (PROSPERO registration number: CRD42019128927) was to evaluate the effectiveness of CZA combination therapy versus CZA monotherapy in the treatment of severe infections. The databases included in the search, until February 12th, 2020, were MEDLINE by PubMed, EMBASE, and The Cochrane Central Register of Controlled Trials. We included both randomized controlled trials (RCTs) and non-randomized studies publish…

0301 basic medicineCarbapenem-resistant enterobacteriaceaeBiochemistrylaw.inventionsepsisCeftazidime‐avibactam0302 clinical medicineRandomized controlled trialsystematic reviewlawPharmacology (medical)030212 general & internal medicineGeneral Pharmacology Toxicology and Pharmaceuticsnetwork meta-analysisceftazidime-avibactamAnti‐infective agentnetwork meta-analysiInfectious Diseasescarbapenem-resistant EnterobacteriaceaeMeta-analysisβ-lactamase inhibitors.sepsimedicine.drugMicrobiology (medical)medicine.medical_specialtyCombination therapyβ-lactamase inhibitors030106 microbiologyMEDLINEβ‐lactamase inhibitorsMicrobiologyArticle03 medical and health sciencesCarbapenem‐resistant Enterobacteriaceaemultidrug resistanceInternal medicinemedicineanti-infective agentbacteremiabusiness.industrylcsh:RM1-950Retrospective cohort studyCeftazidime/avibactammedicine.diseaseinfectionlcsh:Therapeutics. PharmacologyBacteremiaanti-infective agentsbusinessNetwork meta‐analysi
researchProduct